Disruption of endocrine hormonal balance (ie, increased levels of insulin, and reduced
levels of growth hormone, GH) often occurs in pre‐obesity and obesity. Using distinct …

A unique mouse model was developed with elevated endogenous GH (2-to 3-fold) and IGF-I
(1.2-to 1.4-fold), due to somatotrope-specific Cre-mediated inactivation of IGF-I receptor …

Obesity has become one of the most common medical problems in developed countries,
and this disorder is associated with high incidences of hypertension, dyslipidaemia …

Growth hormone (GH), a master regulator of somatic growth, also regulates carbohydrate
and lipid metabolism via complex interactions with insulin and insulin-like growth factor-1 …

Pathological changes associated with obesity are thought to contribute to GH deficiency.
However, recent observations suggest that impaired GH secretion relative to excess calorie …

The last two decades have seen resurgence in research focused on adipose tissue. In part,
the enhanced interest stems from an alarming increase in obesity rates worldwide. However …

There is a negative relationship between obesity and GH. However, it is not known how
metabolic changes, associated with obesity, lead to a reduction in GH output. This study …

There is substantial evidence that the growth hormone (GH)/insulin-like growth factor (IGF)
system is involved in the pathophysiology of obesity. Both GH and IGF-I have direct effects …

IGF-I is considered a primary inhibitor of GH secretion. Insulin may also play an important
role in regulating GH levels because insulin, like IGF-I, can suppress GH synthesis and …

Obesity is a growing public health problem worldwide, and GH and IGF-1 have been studied
as potential therapeutic targets for managing this condition. This review article aims to …